Pyxis Oncology (PYXS) traded up 0.6 % during a 24 hours period ending at 09:47 PM Central Europe on Tuesday 27th. One Pyxis Oncology stock can currently be bought for about USD 1.84 on popular exchanges. Current supply of Pyxis Oncology stocks is 119.5 mn. Pyxis Oncology has a current market capitalization of USD 200.7 mn and approximately USD 1.1 mn worth of Pyxis Oncology was traded on exchanges in the last 24 hours. Since last month end, Pyxis Oncology has traded -41.72 % down. Simple moving average of last 200 days is at USD 2.16. The highest price of past 52 weeks was recorded at USD 5.55 on 11/26/2025. 52 weeks low was at USD 1.03 on 12/26/2025.

Here is how related stocks have performed in the past 24 hours:

  • Optimum Communications (OPTU) traded flat 0 % and now trades at USD 0.62. Optimum Communications has a market capitalisation of USD 239.1 mn. Optimum Communications, Inc. reported a change in beneficial ownership of its Class A common shares. Several reporting parties—Neil Subin, MILFAM LLC, MILFAM GP LLC, and Dark Mirage LP—each hold roughly a fifteenth of the outstanding shares, totaling about thirteen percent ownership. The filing indicates that these parties acquired additional shares in late October, bringing their holdings to just over twenty‑seven hundred thousand shares. The disclosures confirm that the owners are not seeking to influence corporate control and that the transactions are routine adjustments in ownership. No significant change in corporate governance or strategy was noted, and the filing satisfies regulatory requirements for reporting such holdings.

  • Forrester Research (FORR) traded down -1.2 % and now trades at USD 12.02. Current market capitalisation for Forrester Research is USD 238 mn.

  • Greenwich Lifesciences (GLSI) traded up 6.83 % and now trades at USD 17.42. Greenwich Lifesciences has a market capitalisation of USD 237.5 mn. Greenwich LifeSciences, Inc. filed a definitive proxy statement and an annual report to shareholders on October 26, 2026, announcing its upcoming annual meeting on December 18. The proxy materials outline the agenda, which includes the election of five board directors, ratification of the accounting firm MaloneBailey LLP, advisory approval of executive compensation, and discussion of future advisory vote frequency. The company also provided guidance on voting methods and the record date, set for October 26, 2026. The filings highlight the firm’s governance framework, detailing board composition, committee responsibilities, and independence standards, and reaffirm the separation of the chief executive officer and board chair roles. No financial data or market performance is disclosed, and the documents focus on corporate governance and shareholder engagement.

  • Cabaletta Bio (CABA) traded down -8.16 % and now trades at USD 1.46. Cabaletta Bio has a market capitalisation of USD 240.8 mn.

  • Standard Biotools (LAB) traded down -1.64 % and now trades at USD 0.62. Current market capitalisation for Standard Biotools is USD 237.9 mn.

About Pyxis Oncology

Pyxis Oncology, Inc. is a biotech company that specializes in developing novel therapies to assist patients in combating difficult-to-treat cancers. The company operates within the health care sector, providing services to medical professionals in the United States. You can find more information about the company and their activities on their website, which is www.pyxisoncology.com . The company’s stock is traded on the Nasdaq stock exchange.